The Importance of Pharmaceutical Patent Case Sharing

The importance of pharmaceutical patents is to provide a system to protect and stimulate innovation. Some of the main aspects of the importance of pharmaceutical patents, such as the protection of intellectual property rights, patents provide exclusive rights to drugs or treatments, enable pharmaceutical companies to protect their unique innovation and R & D investment, and encourage companies to invest more resources in innovation because they know that successful new drugs will not be subject to competition for a period of time; encourage innovation, the patent system encourages pharmaceutical companies to conduct more research and development to find new treatments and drugs. This competitive environment helps to promote progress in the field of medicine and pharmacy, improve existing treatments or develop new therapies. Return on investment. Pharmaceutical companies invest a lot of money in research and development, and patents provide a way to return on investment. During the patent protection period, companies can sell their drugs on an exclusive supply, to earn enough profits to cover the cost of R & D and clinical trials; to maintain a competitive advantage, having valid patents can help the company build a competitive advantage in the market, which helps prevent other companies from manufacturing similar drugs or treatments, to ensure that the original company can maintain a leading position in the market; to provide commercial bargaining chips, pharmaceutical companies can use their patents as commercial bargaining chips, such as licensing agreements or partnerships with other firms, the following is aboutJohnson & JohnsonCompany.AstellasExamples of companies.

AboutJohnson & JohnsonCompanies are being asked to revoke some requests to protect patents on their TB drugs,Unitaidis a humanitarian organization,Johnson & JohnsonCompany President Hua Jin· Duatto(Joaquin Duato)sent a letter calling for immediate action to expandbedaquilineThe acquisition, which is a modern anti-TB drug, is currentlySIRTUREThe drug, which is marketed under the brand name, is protected by patents, which discourages the emergence of generic drugs,UnitaidAppealJohnson & JohnsonThe company revokes all sub-patents and ensures that the drug is available at a low price in all countries with high TB rates, althoughJohnson & JohnsonThe company has reduced the number of drugs used to treat drug-resistant tuberculosis.bedaquilineprice,UnitaidCalling the decision incomplete because it fails to address the elimination of tuberculosis in a number of countries, including Ukraine,UnitaidThe representative of said that usually organizations do not disclose information about communication with the management of pharmaceutical companies, however, in this case, due to the importance of the issue, this is an exception.

In addition, in the recentJohnson & JohnsonThe company has resolvedStelara.The patent dispute is aboutAlvotechandTevaalreadyJohnson & JohnsonThe company has signed a global agreement over a patent dispute over a popular monoclonal antibody, under the terms of which generic drug makers will be given access to biosimilar drugs in the U.S. market.AVT04Right, no later.More2025Year2Month21Day, before that,Johnson & JohnsonThe company resolved the relationshipAmgenThe company obtained a legal dispute in2025Year1Month1Recently released its biosimilar drugStelara (ustekinumab)rights, as of now, whetherAmgenThe drugs or.TevaandAlvotechThe generic drugs are not yet available.FDAof approval, the manufacturer claims to have submittedAVT04 (ustekinumab)and the decision on the drug will be announced in the second half of the year, however.2023Year10month,FDAReject approvalAVT04The application.

Another example is aboutAstellasCompany failed to protect one of its best-selling drugs, and a U.S. court has ruled that a treatment owned by the companyMyrbetriqThe company said it would appeal the ruling, in a case heard in Delaware District Court that focused on U.S. patent No.10,842,780of patents, relating to as2030years of long-term releaseMyrbetriqpreparation, the Japanese pharmaceutical company asked the court to rule that the generic drug infringed the patent,MyrbetriqIt is a drug for the treatment of overactive bladder with symptoms of urinary incontinence, urgent urination and frequent urination. It is used in some markets.BetanisandBetmigaThe name of the sale, since2012years since,Myrbetriqhave been used in the clinic and have since becomeAstellasOne of the best-selling drugs, in the last fiscal year alone, its global sales revenue was approximately13.5Several generic products of the drug have been approved in the United States, includingZydus CadilaandLupine LabsHowever, in viewAstellasPlans to take the case to the Federal Circuit Court of Appeals (CAFC), their listing plans may be threatened, and the company's new CEO, Naoki Okamura, will face another problem, namely the company's important productsXtandiWill be2027years of losing patent protection, which is undoubtedlyAstellasof the main products, sales in the previous fiscal year reached47.5Billions of dollars.

Overall, patents are an important driver of innovation and business success for pharmaceutical companies, but they also need to be balanced to ensure that patients have access to appropriate medical care, such as price and accessibility. Patent protection enables pharmaceutical companies to sell their drugs at higher prices during the patent period to compensate for research and development costs. However, this may also make it difficult for some patients to afford expensive drugs, it is necessary to ensure the accessibility of drugs to the public through different pricing and marketing strategies while ensuring the profits of pharmaceutical companies. Rational use of patent rights: pharmaceutical companies should exercise their patent rights in a responsible manner and not abuse their monopoly position. This may include cooperation with academic institutions and other pharmaceutical companies to improve the level of innovation and expand the benefits of patient groups. Authorization and cooperation: Pharmaceutical companies can cooperate with other companies through authorization or with other companies, improve the efficiency of drug production and supply, while expanding the scope of benefits for patients; Later-stage market competition, with the end of the patent protection period, the latter-stage market will usually usher in more competition, reduce prices and increase patient choices, which helps improve drug accessibility. Therefore, while promoting innovation and business success, patents need to focus on public interests and ensure that patients can obtain necessary treatments and drugs.